and 3) stopping therapy commonly leads to partial or full weight regain, underscoring obesitys chronic nature and the need for long-term strategies
Major cardiovascular outcome trials include: LEADER trial (liraglutide): Demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk SUSTAIN-6 (semaglutide): Showed reduced cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke REWIND (dulaglutide): Confirmed cardiovascular benefits across a broad patient population SELECT trial (semaglutide): Showed reduced MACE in people with obesity without diabetes, though this evidence is not yet fully incorporated into UK labelling [17] These trials consistently found that the modest heart rate increases observed did not translate into adverse cardiovascular outcomes
These ten diseases accounted for over 50% of recent R&D activity in the rare disease field 14
By suppressing the enzyme tyrosinase, which is crucial for melanin production, glutathione helps reduce pigmentation
Instead, it develops from a combination of factors: Stressful Life Events
Heres everything you need to know about Saxenda side effects